Stegent Equity Advisors Inc. Has $2.50 Million Stock Position in AbbVie Inc. $ABBV

Stegent Equity Advisors Inc. increased its position in shares of AbbVie Inc. (NYSE:ABBV) by 209.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,929 shares of the company’s stock after acquiring an additional 7,400 shares during the quarter. AbbVie accounts for about 1.9% of Stegent Equity Advisors Inc.’s holdings, making the stock its 11th largest position. Stegent Equity Advisors Inc.’s holdings in AbbVie were worth $2,497,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Vanguard Group Inc. lifted its holdings in shares of AbbVie by 0.3% in the third quarter. Vanguard Group Inc. now owns 177,747,261 shares of the company’s stock valued at $41,155,601,000 after purchasing an additional 448,554 shares in the last quarter. Legal & General Group Plc grew its holdings in shares of AbbVie by 4.3% during the third quarter. Legal & General Group Plc now owns 12,004,084 shares of the company’s stock valued at $2,779,426,000 after buying an additional 493,420 shares in the last quarter. Wellington Management Group LLP raised its position in AbbVie by 457.4% during the third quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company’s stock valued at $2,439,714,000 after buying an additional 8,646,424 shares during the period. Amundi raised its position in AbbVie by 15.6% during the third quarter. Amundi now owns 10,508,317 shares of the company’s stock valued at $2,418,909,000 after buying an additional 1,414,621 shares during the period. Finally, Ameriprise Financial Inc. lifted its stake in AbbVie by 4.4% in the 3rd quarter. Ameriprise Financial Inc. now owns 9,675,877 shares of the company’s stock worth $2,241,363,000 after acquiring an additional 408,426 shares in the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Insider Activity at AbbVie

In other news, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the transaction, the executive vice president owned 38,137 shares in the company, valued at $8,771,510. This represents a 36.98% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP David Ryan Purdue sold 5,230 shares of the firm’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the transaction, the senior vice president owned 2,654 shares in the company, valued at $619,868.24. This represents a 66.34% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 0.08% of the company’s stock.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Company outlook and dividend expectations — Analysts and commentators highlight AbbVie’s strong 2026 guidance and the likelihood of future dividend increases, driven by cash flow from Humira/Imbruvica/oncology and growth in the dermatology portfolio; that narrative supports income investors and dividend yield buyers. AbbVie: Strong 2026 Outlook, Expect Dividend Increases
• Positive Sentiment: Clinical and real‑world data boost dermatology franchise — AbbVie announced new clinical and real‑world evidence for risankizumab (psoriasis/psoriatic arthritis) and upadacitinib (atopic dermatitis), plus Phase‑3 data for vitiligo and alopecia areata to be presented at AAD 2026. Strong safety/efficacy reads can support durable revenue and reduce investor uncertainty around launches. AbbVie to Highlight New Clinical and Real-World Evidence…
• Positive Sentiment: Analyst estimate tweak — Erste Group modestly raised its FY2027 EPS estimate for AbbVie, signaling incremental confidence in earnings power (small change but supportive vs. downside fears). MarketBeat AbbVie Profile
• Neutral Sentiment: Allergan Aesthetics (AbbVie unit) scientific presence — Allergan is presenting multiple evidence‑based posters and product positioning (JUVÉDERM, HA injectables) at AMWC, reinforcing aesthetics growth and brand leadership but with limited immediate revenue impact. Allergan Aesthetics Reinforces Scientific Differentiation…
• Neutral Sentiment: Dividend yield framing for investors — Retail‑focused pieces (The Motley Fool) calculate how many ABBV shares generate targeted dividend income; useful for income investors but not an earnings catalyst. Here’s How Many Shares of AbbVie (ABBV) Stock You’d Need…
• Negative Sentiment: Recent price weakness & value debate — Coverage noting recent share‑price declines and questions about valuation may pressure sentiment in the short term; headline focus on near‑term multiple compression can spur selling even as fundamentals are debated. Is AbbVie (ABBV) Now Offering Value After Recent Share Price Weakness?

Analyst Ratings Changes

A number of equities research analysts have commented on ABBV shares. William Blair restated an “outperform” rating on shares of AbbVie in a research report on Monday, March 9th. HSBC raised shares of AbbVie from a “hold” rating to a “buy” rating and increased their price target for the stock from $225.00 to $265.00 in a research report on Wednesday, December 10th. The Goldman Sachs Group restated a “neutral” rating and set a $223.00 price target on shares of AbbVie in a report on Wednesday, January 28th. BMO Capital Markets reiterated an “outperform” rating on shares of AbbVie in a research note on Monday, March 9th. Finally, Berenberg Bank set a $275.00 target price on shares of AbbVie in a research report on Tuesday, January 20th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $253.15.

AbbVie Price Performance

Shares of ABBV stock opened at $209.46 on Monday. AbbVie Inc. has a fifty-two week low of $164.39 and a fifty-two week high of $244.81. The stock’s 50-day moving average is $221.96 and its two-hundred day moving average is $224.71. The firm has a market cap of $370.37 billion, a P/E ratio of 88.76, a PEG ratio of 0.73 and a beta of 0.34.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.65 by $0.06. The business had revenue of $16.62 billion during the quarter, compared to analyst estimates of $16.39 billion. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The firm’s revenue was up 10.0% on a year-over-year basis. During the same period in the previous year, the company earned $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, research analysts expect that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be paid a $1.73 dividend. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a yield of 3.3%. AbbVie’s payout ratio is 293.22%.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.